Treatment Of RB-Negative Tumors Using Topoisomerase Inhibitors In Combination With Cyclin Dependent Kinase 4/6 Inhibitors
AssigneeG1 Therapeutics, Inc.
InventorsJay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino
Life of this patent
Estimating the term…
Abstract
This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. In one aspect, the improved treatment of select Rb-negative cancers is disclosed using specific compounds disclosed herein in combination with a topoisomerase I inhibitor.
Claims34
A method for treating a host having triple negative breast cancer comprising administering an effective amount of a topoisomerase inhibitor selected from topotecan, etirinotecan pegol, belotecan, cositecan, and irinotecan and a CDK 4/6 inhibitor compound selected from:
- or a pharmaceutically acceptable salt therein.
A method for treating a host having RB-negative cervical cancer comprising administering an effective amount of a chemotherapeutic agent selected from topotecan, etirinotecan pegol, belotecan, cositecan, and irinotecan and a CDK 4/6 inhibitor compound selected from:
- or a pharmaceutically acceptable salt therein.
A method for treating a host having small cell lung cancer comprising administering an effective amount of a chemotherapeutic agent selected from belotecan, etirinotecan pegol, and cositecan and a CDK 4/6 inhibitor compound selected from:
- or a pharmaceutically acceptable salt therein.
Dependencies are inferred from the claim text.